Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Jul 7

PMID 35795364

Authors

Rui Hua

Ning Ding

Hanqing Guo

Yue Wu

Zuyi Yuan

Ting Li

Affiliations

Soon will be listed here.

Abstract

Background: Contrast-induced acute kidney injury (CI-AKI) is a common complication of patients undergoing percutaneous coronary intervention (PCI). Data regarding the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitor on the CI-AKI incidence and renal outcomes of patients undergoing PCI are limited. This study aimed to examine the real-world risk of CI-AKI in SGLT2 inhibitor users undergoing PCI.

Methods: We used longitudinal data from the medical records of the First Affiliated Hospital of Xi'an Jiaotong University. We selected SGLT inhibitor users and nonusers [patients with type 2 diabetes (T2D) without SGLT2 inhibitor prescription] undergoing PCI. We determined CI-AKI by the ESUR (European Society of Urogenital Radiology, AKI) and KDIGO definition (Kidney Disease: Improving Global Outcomes, AKI). We performed 1:1 nearest-neighbor propensity matching and calculated unadjusted odds ratios (ORs) and adjusted ORs (aORs; accounting for covariates poorly balanced) for AKI in primary and sensitivity analyses. We compared the renal function indicators in users and nonusers at 24, 48, and 72 h post-PCI.

Results: We identified 242 SGLT2 inhibitor users and 242 nonusers in the cohort. The unadjusted ORs of CI-AKI were 63% lower in users [OR: 0.37 (95% CI: 0.18-0.68); = 0.01], which was unchanged [aOR: 0.37 (95% CI: 0.19-0.67); < 0.01] post adjustment. These estimates did not qualitatively change across several sensitivity analyses. There was no significant difference in urea nitrogen, creatinine, and estimated glomerular filtration rate (eGFR) values between the two groups before PCI, and at 24 h, while the creatinine (48 and 72 h post-PCI) and CyC (24 and 48 h post-PCI) were significantly lower than those in the nonuser group ( < 0.05).

Conclusion: Our findings do not suggest an increased risk of CI-AKI associated with SGLT2 inhibitor use in patients with CAD and T2D undergoing PCI.

Citing Articles

Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial.

Hosseini Z, Jamili M, Ensan B, Donyadideh G, Shahri B, Eshraghi H Sci Rep. 2025; 15(1):3940.

PMID: 39890841 PMC: 11785941. DOI: 10.1038/s41598-024-82991-7.

Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis.

Ansari H, Samad M, Mahboob E, Zulfiqar E, Qazi S, Ahsan A Am J Prev Cardiol. 2025; 21:100927.

PMID: 39867488 PMC: 11757226. DOI: 10.1016/j.ajpc.2024.100927.

Sodium-glucose cotransporter 2 inhibitors and contrast-induced nephropathy risk: a meta-analysis.

Fan G, Lin L, Zuo H, Yan R, Xu C Eur J Clin Pharmacol. 2024; 81(3):337-345.

PMID: 39729107 DOI: 10.1007/s00228-024-03799-y.

SGLT2 Inhibitors and the Risk of Contrast-Associated Nephropathy Following Angiographic Intervention: Contradictory Concepts and Clinical Outcomes.

Heyman S, Aronson D, Abassi Z Int J Mol Sci. 2024; 25(19).

PMID: 39409086 PMC: 11477343. DOI: 10.3390/ijms251910759.

Efficacy of Chronic Use of Sodium-Glucose Co-transporter 2 Inhibitors on the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Type 2 Diabetes Mellitus Following Coronary Procedures: A Systematic Review and Meta-Analysis.

Dimitriadis K, Vakka A, Pyrpyris N, Apostolos A, Beneki E, Stathopoulou E Am J Cardiovasc Drugs. 2024; 25(1):57-69.

PMID: 39392560 DOI: 10.1007/s40256-024-00684-y.

References

Mehran R, Aymong E, Nikolsky E, Lasic Z, Iakovou I, Fahy M . A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44(7):1393-9. DOI: 10.1016/j.jacc.2004.06.068. View

James M, Ghali W, Knudtson M, Ravani P, Tonelli M, Faris P . Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation. 2011; 123(4):409-16. DOI: 10.1161/CIRCULATIONAHA.110.970160. View

Patoulias D, Boulmpou A, Papadopoulos C, Doumas M . Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?. Kidney Med. 2021; 3(4):674-675. PMC: 8350837. DOI: 10.1016/j.xkme.2021.02.014. View

Hua R, Li Y, Li W, Wei Z, Yuan Z, Zhou J . Apolipoprotein B/A1 Ratio Is Associated with Severity of Coronary Artery Stenosis in CAD Patients but Not in Non-CAD Patients Undergoing Percutaneous Coronary Intervention. Dis Markers. 2021; 2021:8959019. PMC: 8710153. DOI: 10.1155/2021/8959019. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

van Baar M, van Ruiten C, Muskiet M, van Bloemendaal L, IJzerman R, van Raalte D . SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care. 2018; 41(8):1543-1556. DOI: 10.2337/dc18-0588. View

Zhuo M, Paik J, Wexler D, Bonventre J, Kim S, Patorno E . SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Am J Kidney Dis. 2021; 79(6):858-867.e1. PMC: 9079190. DOI: 10.1053/j.ajkd.2021.09.015. View

Gassanov N, Nia A, Caglayan E, Er F . Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option?. J Am Soc Nephrol. 2013; 25(2):216-24. PMC: 3904574. DOI: 10.1681/ASN.2013070708. View

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

10.

Hahn K, Ejaz A, Kanbay M, Lanaspa M, Johnson R . Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016; 12(12):711-712. DOI: 10.1038/nrneph.2016.159. View

11.

Salah H, AlAref S, Khan M, Al-Hawwas M, Vallurupalli S, Mehta J . Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022; 21(1):20. PMC: 8817537. DOI: 10.1186/s12933-022-01455-2. View

12.

Nadkarni G, Ferrandino R, Chang A, Surapaneni A, Chauhan K, Poojary P . Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care. 2017; 40(11):1479-1485. PMC: 5652593. DOI: 10.2337/dc17-1011. View

13.

Maioli M, Toso A, Leoncini M, Musilli N, Grippo G, Ronco C . Bioimpedance-Guided Hydration for the Prevention of Contrast-Induced Kidney Injury: The HYDRA Study. J Am Coll Cardiol. 2018; 71(25):2880-2889. DOI: 10.1016/j.jacc.2018.04.022. View

14.

Chalikias G, Drosos I, Tziakas D . Contrast-Induced Acute Kidney Injury: An Update. Cardiovasc Drugs Ther. 2016; 30(2):215-28. DOI: 10.1007/s10557-015-6635-0. View

15.

Kellum J, Lameire N . Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013; 17(1):204. PMC: 4057151. DOI: 10.1186/cc11454. View

16.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

17.

Mosenzon O, Wiviott S, Cahn A, Rozenberg A, Yanuv I, Goodrich E . Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019; 7(8):606-617. DOI: 10.1016/S2213-8587(19)30180-9. View

18.

Tomasoni D, Fonarow G, Adamo M, Anker S, Butler J, Coats A . Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021; 24(3):431-441. PMC: 9303969. DOI: 10.1002/ejhf.2397. View

19.

. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2019; 43(Suppl 1):S98-S110. DOI: 10.2337/dc20-S009. View

20.

Maron D, Hochman J, Reynolds H, Bangalore S, OBrien S, Boden W . Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020; 382(15):1395-1407. PMC: 7263833. DOI: 10.1056/NEJMoa1915922. View